Left ventricular hypertrophy and renin-angiotensin-aldosterone system: AT1-receptor blockers are in the focus | Zendy

А. В. Барсуков | Zendy; D. V. Glukhovskoy | Zendy; М. С. Таланцева | Zendy; З. В. Багаева | Zendy; Е. Pronina | Zendy; М. П. Зобнина | Zendy; Т. С. Свеклина | Zendy; А Е Коровин | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Left ventricular hypertrophy and renin-angiotensin-aldosterone system: AT1-receptor blockers are in the focus

Author(s) -

А. В. Барсуков,

D. V. Glukhovskoy,

М. С. Таланцева,

З. В. Багаева,

Е. Pronina,

М. П. Зобнина,

Т. С. Свеклина,

А Е Коровин

Publication year - 2013

Publication title -

systemic hypertension

Language(s) - English

Resource type - Journals

eISSN - 2542-2189

pISSN - 2075-082X

DOI - 10.26442/sg28961

Subject(s) - left ventricular hypertrophy , medicine , cardiology , ventricle , telmisartan , renin–angiotensin system , muscle hypertrophy , angiotensin ii receptor type 1 , aldosterone , essential hypertension , blood pressure

Left ventricular hypertrophy (LVH) is one of the cardio-vascular continuum components, determining the prognosis of patient with essential hypertension (EH). Pathogenesis of LVH has a multifactor character. Important role in development of cardiomyocites hypertrophy, Intracardiac fibrosis, left ventricle cavity dilation belongs to renin-angiotensin-aldosteron system (RAAS). Pharmacologic blockade of RAAS composes the basis of therapy, directed to LVH regress. Application of Telmisartan is considered high-reasonable approach to treatment of EH-patient with LVH.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research